BACKGROUND: Sleeve gastrectomy (SG) is an upcoming primary treatment modality for morbid obesity. The aim of this study was to report the indications for and the outcomes of revisional surgery after SG. METHODS: Four hundred sixteen individuals underwent a SG between August 2006 and July 2010 with a minimum follow-up of 12 months. The patients that needed revision were identified from our prospective registry. Patients were subdivided in a first group undergoing revision as part of a two-step procedure, a second group with failure of a secondary SG, and a third group with failure of a primary SG. RESULTS: Twenty-three patients (5.5%) had an unplanned revision. Fourteen (3.4%) had a two-step procedure because of super obesity. A significant additional weight loss was achieved after revision; no complications occurred in this group. Five patients with failure of a secondary SG had no significant additional weight loss after revision. Reflux disease was cured. Eighteen patients in the third group showed significant additional weight loss and remission of diabetes and hypertension. Both reflux disease and dysphagia did not heal in all affected patients after revision. The early complication rate in the whole cohort was 23.4%; staple line leakage was 5.4%, and bleeding was 8.1%. Revision-related mortality was 0%. CONCLUSION: In a large series of sleeve gastrectomies, the unplanned revision rate was 5.5%. Revision of a sleeve gastrectomy is feasible in patients that do not achieve sufficient weight loss and in those patients developing complications after the initial sleeve gastrectomy.
BACKGROUND: Sleeve gastrectomy (SG) is an upcoming primary treatment modality for morbid obesity. The aim of this study was to report the indications for and the outcomes of revisional surgery after SG. METHODS: Four hundred sixteen individuals underwent a SG between August 2006 and July 2010 with a minimum follow-up of 12 months. The patients that needed revision were identified from our prospective registry. Patients were subdivided in a first group undergoing revision as part of a two-step procedure, a second group with failure of a secondary SG, and a third group with failure of a primary SG. RESULTS: Twenty-three patients (5.5%) had an unplanned revision. Fourteen (3.4%) had a two-step procedure because of super obesity. A significant additional weight loss was achieved after revision; no complications occurred in this group. Five patients with failure of a secondary SG had no significant additional weight loss after revision. Reflux disease was cured. Eighteen patients in the third group showed significant additional weight loss and remission of diabetes and hypertension. Both reflux disease and dysphagia did not heal in all affected patients after revision. The early complication rate in the whole cohort was 23.4%; staple line leakage was 5.4%, and bleeding was 8.1%. Revision-related mortality was 0%. CONCLUSION: In a large series of sleeve gastrectomies, the unplanned revision rate was 5.5%. Revision of a sleeve gastrectomy is feasible in patients that do not achieve sufficient weight loss and in those patients developing complications after the initial sleeve gastrectomy.
Authors: Patrice R Carter; Karl A LeBlanc; Mark G Hausmann; Kenneth P Kleinpeter; Sean N deBarros; Shannon M Jones Journal: Surg Obes Relat Dis Date: 2011-03-22 Impact factor: 4.734
Authors: Mario P Morales; Andrew A Wheeler; Archana Ramaswamy; J Stephen Scott; Roger A de la Torre Journal: Surg Obes Relat Dis Date: 2010-01-01 Impact factor: 4.734
Authors: Christine Stroh; Dieter Birk; Ricarda Flade-Kuthe; Michael Frenken; Beate Herbig; Stefan Hohne; Hinrich Kohler; Volker Lange; Kaja Ludwig; Ralf Matkowitz; Gunther Meyer; Frank Meyer; Peter Pick; Thomas Horbach; Stefan Krause; Lothar Schafer; Matthias Schlensak; Edward Shah; Thomas Sonnenberg; Martin Susewind; Hans Voigt; Rudolf A Weiner; Stefanie Wolff; Hans Lippert; Anna Maria Wolf; Uwe Schmidt; Thomas Manger Journal: Obes Facts Date: 2009-03-18 Impact factor: 3.942
Authors: N L De Groot; J S Burgerhart; P C Van De Meeberg; D R de Vries; A J P M Smout; P D Siersema Journal: Aliment Pharmacol Ther Date: 2009-09-16 Impact factor: 8.171
Authors: Chetan D Parmar; Kamal K Mahawar; Maureen Boyle; Norbert Schroeder; Shlok Balupuri; Peter K Small Journal: Obes Surg Date: 2017-07 Impact factor: 4.129